GS
CHNA

GTS Securities’s Loncar China BioPharma ETF CHNA Stock Holding History

GTS Securities’s Portfolio CHNA Stock Details CHNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,727
Closed -$267K – 4559
2023
Q3 		$267K Buy
18,727
+3,334
+22% +$51K ﹤0.01% 3162
2023
Q2 		$249K Buy
+15,393
New +$267K 0.01% 965

GTS Securities's CHNA Position: Q4 2023 in Review

GTS Securities sold out of Loncar China BioPharma ETF (CHNA) in Q4 2023, closing a stake of 18,727 shares — an estimated $267K sold.

GTS Securities first reported a position in CHNA in Q2 2023 and held it in 2 quarters. The position peaked at $267K in Q3 2023. 0 funds tracked by Wall St. Rank hold CHNA as of Q4 2023.

  • GTS Securities reported no remaining Loncar China BioPharma ETF position as of Q4 2023 after selling out during the quarter.
  • GTS Securities sold 18,727 Loncar China BioPharma ETF shares in Q4 2023, an estimated $267K.
  • GTS Securities first reported a position in Loncar China BioPharma ETF in Q2 2023 and held it in 2 quarters.
  • GTS Securities's Loncar China BioPharma ETF position peaked at $267K in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.